Hemodynamic and inflammatory markers of sleep apnea-hypopnea syndrome and nocturnal hypoxemia: Effects of treatment with nasal continuous positive airway pressure

Archivos de Bronconeumologia

Volumn 44, Issue 10, 2008, Pages 531-539

  Sánchez, Amparo ^a   Schwartz, Alan R ^b   Sánchez, Pedro L ^c   Fernández, José L ^a   Ramos, Jacinto ^a   Martín Herrero, Francisco ^a   González Celador, Rafael ^d   Ruano, Ricardo ^d   Bregón, Irene ^a   Martín Luengo, Cándido ^a   Gómez, Francisco P ^a  

^a HOSPITAL UNIVERSITARIO DE SALAMANCA   (Spain)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑÓN   (Spain)

^d NONE

Author keywords

Hypoxemia; Inflammation; ProBNP; Sleep apnea

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; C REACTIVE PROTEIN; BRAIN NATRIURETIC PEPTIDE; PEPTIDE FRAGMENT; PRO BRAIN NATRIURETIC PEPTIDE (1 76); PRO-BRAIN NATRIURETIC PEPTIDE (1-76); UNCLASSIFIED DRUG;

ADULT; ARTERIAL OXYGEN SATURATION; ARTICLE; BLOOD PRESSURE MEASUREMENT; BODY MASS; CARDIOVASCULAR RISK; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; ECHOCARDIOGRAPHY; EPWORTH SLEEPINESS SCALE; FEMALE; HEART LEFT VENTRICLE FAILURE; HEMODYNAMIC PARAMETERS; HUMAN; HYPOXEMIA; MALE; NOCTURNAL HYPOXEMIA; POLYSOMNOGRAPHY; POSITIVE END EXPIRATORY PRESSURE; PROTEIN BLOOD LEVEL; SCINTIGRAPHY; SLEEP APNEA SYNDROME; SMOKING HABIT; TREATMENT OUTCOME; BLOOD; COMPARATIVE STUDY; HEMODYNAMICS; INFLAMMATION; MIDDLE AGED; PATHOPHYSIOLOGY; PROSPECTIVE STUDY;

ADULT; C-REACTIVE PROTEIN; CONTINUOUS POSITIVE AIRWAY PRESSURE; FEMALE; HEMODYNAMICS; HUMANS; INFLAMMATION; MALE; MIDDLE AGED; NATRIURETIC PEPTIDE, BRAIN; PEPTIDE FRAGMENTS; PROSPECTIVE STUDIES; SLEEP APNEA SYNDROMES;

EID: 55049105450     PISSN: 03002896     EISSN: 15792129     Source Type: Journal    
DOI: 10.1157/13126833     Document Type: Article

References (37)

1. Shahar E, Whitney CW, Redline S, Lee ET, Newman AB, Nieto FJ, et al. Sleep-disordered breathing and cardiovascular disease: cross-sectional results of the Sleep Heart Health Study. Am J Respir Crit Care Med. 2001;163:19-25.
2. Lavie P, Hever P, Peled R, Berger I, Yoffe N, Zomer J, et al. Mortality in sleep apnea patients: a multivariate analysis of risk factors. Sleep. 1995;18:149-57.
3. Peppard PE, Young T, Palta M, Skatrud J. Prospective study of the association between sleep-disordered breathing and hypertension. N Engl J Med. 2000;342:1378-84.
4. Chan J, Sanderson J, Chan W, Lai C, Choy D, Ho A, et al. Prevalence of sleep-disordered breathing in diastolic heart failure. Chest. 1997;111:1488-93.
5. Fung JWH, Li TST, Choy DKL, Yip GWK, Ko FWS, Sanderson JE, et al. Severe obstructive sleep apnea is associated with left ventricular diastolic dysfunction. Chest. 2002;121:422-9.
6. Arias MA, García-Río F, Alonso-Fernández A, Mediano O, Martínez I, Villamor J. Obstructive sleep apnea syndrome affects left ventricular diastolic function. Circulation. 2005;112:375-83.
7. McDonagh TA, Robb SD, Murdoch DR, Morton JJ, Ford I, Morrison CE, et al. Biochemical detection of left ventricular systolic dysfunction. Lancet. 1998;351:9-13.
8. Maisel AS, Koon J, Krishnaswamy P, Kazenegra R, Clopton P, Gardetto N, et al. Utility of B-natriuretic peptide as a rapid, point-of-care test for screen patients undergoing echocardiography to determine left ventricular dysfunction. Am Heart J. 2001;141:367-74.
9. Struthers AD. How to use natriuretic peptide levels for diagnosis and prognosis. Eur Heart J. 1999;20:1374-5.
10. Nakamura T, Sakamoto K, Yamano T, Kikkawa M, Zen K, Hikosaka T, et al. Increased plasma brain natriuretic peptide level as a guide for silent myocardial ischemia in patients with non-obstructive hypertrophic cardiomyopathy. J Am Coll Cardiol. 2002;39:1657-63.
11. Silver MA, Maisel A, Yancy CW, McCullough PA, Burnett JC Jr, Francis GS, et al. BNP Consensus Panel 2004: a clinical approach for the diagnostic, prognostic, screening, treatment monitoring, and therapeutic roles of natriuretic peptides in cardiovascular diseases. Congest Heart Fail. 2004;10 Suppl 3:1-30.
12. Yeo KT, Wu AH, Apple FS, Kroll MH, Christenson RH, Lewandrowski KB, et al. Multicenter evaluation of the Roche NTproBNP assay and comparison to the Biosite Triage BNP assay. Clin Chim Acta. 2003;338:107-15.
13. Burke AP, Tracy RP, Kolodgie F, Malcom GT, Zieske A, Kutys R, et al. Elevated C-reactive protein values and atherosclerosis in sudden coronary death: association with different pathologies. Circulation. 2002;105:2019-23.
14. Shamsuzzaman AS, Winnicki M, Lanfranchi P, Wolk R, Kara T, Accurso V, et al. Elevated C-reactive protein in patients with obstructive sleep apnea. Circulation. 2002;105:2462-4.
15. Yokoe T, Minoguchi K, Matsuo H, Oda N, Minoguchi H, Yoshino G, et al. Elevated levels of C-reactive protein and interleukin-6 in patients with obstructive sleep apnea syndrome are decreased by nasal continuous positive airway pressure. Circulation. 2003;107:1129-34.
16. Visser M, Bouter LM, McQuillan GM, Wener MH, Harris TB. Elevated C-reactive protein levels in overweight and obese adults. JAMA. 1999;282:2131-5.
17. American Academy of Sleep Medicine Task Force. Sleep-related breathing disorders in adults: recommendations for syndrome definitions and measurements techniques in clinical research: the report of an American Academy of Sleep Medicine Task Force. Sleep. 1999;22:667-89.
18. Rechtshaffen A, Kales A. A manual of standardized terminology, techniques and scoring system for sleep stages of human subjects. Los Angeles, CA: Brain Information Service, Brain Information Institute, University of California; 1968. p. 1-12.
19. Chiner E, Arriero JM, Signes-Costa J, Marco J, Fuentes I. Validación de la versión española del test de somnolencia de Epworth en pacientes con síndrome de apnea del sueño. Arch Bronconeumol. 1999;35:422-7.
20. Hanly P, Sasson Z, Zuberi N, Alderson M. Ventricular function in snorers and patients with obstructive sleep apnea. Chest. 1992;102:100-5.
21. Niroumand M, Kuperstein R, Sasson Z, Hanly PJ. Impact of obstructive sleep apnea on left ventricular mass and diastolic function. Am J Respir Crit Care Med. 2001;163:1632-6.
22. Alchanatis M, Tourkohoriti G, Kosmas EN, Panoutsopoulos G, Kakouros S, Papadima K, et al. Evidence for left ventricular dysfunction in patients with obstructive sleep apnoea syndrome. Eur Respir J. 2002;20:1239-45.
23. Svatikova A, Shamsuzzaman A, Wolk R, Phillips B, Olson L, Somers V. Plasma brain natriuretic peptide in obstructive sleep apnea. Am J Cardiol. 2004;94:529-32.
24. Tasci S, Manka R, Scholtyssek S, Lentini S, Troatz C, Stoffel-Wagner B, et al. NT-pro-BNP in obstructive sleep apnea syndrome is decreased by nasal continuous positive airway pressure. Clin Res Cardiol. 2006;95:23-30.
25. Goetze JP, Christoffersen C, Perko M, Arendrup H, Rehfeld JF, Kastrup J, et al. Increased cardiac BNP expression associated with myocardial ischemia. FASEB J. 2003;17:1105-7.
26. Goetze JP, Gore A, Moller CH, Steinbruchel DA, Rehfeld JF, Nielsen LB. Acute myocardial hypoxia increases BNP gene expression. FASEB J. 2004;18:1928-30.
27. Wong CY, O'Moore-Sullivan T, Leano R, Byrne N, Beller E, Marwick TH. Alterations of left ventricular myocardial characteristics associated with obesity. Circulation. 2004;110:3081-7.
28. Costello-Boerrigter LC, Boerrigter G, Redfield MM, Rodeheffer RJ, Urban LH, Mahoney DW, et al. Amino-terminal pro-B-type natriuretic peptide and B-type natriuretic peptide in the general community. J Am Coll Cardiol. 2006;47:345-53.
29. Das SR, Drazner MH, Dries DL, Vega GL, Stanek HG, Abdullah SM, et al. Impact of body mass and body composition on circulating levels of natriuretic peptides: results from the Dallas Heart Study. Circulation. 2005;112:2163-8.
30. Can M, Acikgoz S, Mungan G, Bayraktaroglu T, Kocak E, Guven B, et al. Serum cardiovascular risk factors in obstructive sleep apnea. Chest. 2006;129:233-7.
31. Vgontzas AN, Papanicolau DA, Bixler EO, Kales A, Tyson K, Chrousos GP. Elevation of plasma cytokines in disorders of excessive daytime sleepiness: role of sleep disturbance and obesity. J Clin Endocrinol Metab. 1997;82:1313-6.
32. Ryan S, Nolan G, Hannigan E, Cunningham S, Taylor CT, McNicholas WT. Cardiovascular risk markers in obstructive sleep apnoea syndrome and correlation with obesity. Thorax. 2007;62:509-14.
33. Akashiba T, Akahoshi T, Kawahara S, Majima T, Horie T. Effects of long-term nasal continuous positive airway pressure on C-reactive protein in patients with obstructive sleep apnea syndrome. Intern Med. 2005;44:899-900.
34. Guillemin K, Krasnow MA. The hypoxic response: huffing and HIFing. Cell. 1997;89:9-12.
35. Ryan S, Taylor CT, McNicholas WT. Predictors of elevated nuclear factor-b-dependent genes in obstructive sleep apnea syndrome. Am J Respir Crit Care Med. 2006;174:824-30.
36. Pepperell J, Stradling J, Davies R. Brain natriuretic peptide is unchanged after 4 weeks of continuous positive airway pressure therapy. J Sleep Res. 2006;15:463-4.
37. Javaheri S. Effects of continuous positive airway pressure on sleep apnea and ventricular irritability in patients with heart failure. Circulation. 2000;101:392-7.